Minoru Satoh

List of Publications by Year in Descending Order

182 papers	8,127 citations	47 h-index	85 g-index
195 ext. papers	9,288 ext. citations	5.6 avg, IF	5.74 L-index

#	Paper	IF	Citations
182	Anti-synthetase syndrome occurring after SARS-CoV-2 infection.. *Scandinavian Journal of Rheumatology*, **2022**, 1-3	1.9	0
181	The International Consensus on ANA Patterns (ICAP) in 2021-The 6th Workshop and Current Perspectives.. *journal of applied laboratory medicine, The*, **2022**, 7, 322-330	2	6
180	Antigen Reactivity and Clinical Significance of Autoantibodies Directed Against the Pyruvate Dehydrogenase Antigen Complex in Patients With Connective Tissue Disease.. *Frontiers in Immunology*, **2022**, 13, 822996	8.4	0
179	Myositis with prominent B-cell aggregates causing shrinking lung syndrome in systemic lupus erythematosus: a case report.. *BMC Rheumatology*, **2022**, 6, 11	2.9	0
178	Autoimmune pulmonary alveolar proteinosis exacerbated by steroid therapy due to misdiagnosis as anti-aminoacyl-tRNA synthetase (ARS) antibody positive- interstitial pneumonia: a case report.. *BMC Pulmonary Medicine*, **2022**, 22, 120	3.5	1
177	Comment on: Concordance between myositis autoantibodies and anti-nuclear antibody patterns in a real-world, Australian cohort.. *Rheumatology*, **2022**,	3.9	1
176	Comment on: Favourable complete remission of anti-OJ antibody-positive myositis after lung cancer resection.. *Rheumatology*, **2022**,	3.9	1
175	Development of Rheumatoid Arthritis During Anti-Interleukin-5 Therapy in a Patient with Refractory Chronic Eosinophilic Pneumonia. *Journal of Asthma and Allergy*, **2021**, 14, 1425-1430	3.1	1
174	How to report the antinuclear antibodies (anti-cell antibodies) test on HEp-2 cells: guidelines from the ICAP initiative. *Immunologic Research*, **2021**, 69, 594-608	4.3	11
173	The DNA co-vaccination using Sm antigen and IL-10 as prophylactic experimental therapy ameliorates nephritis in a model of lupus induced by pristane. *PLoS ONE*, **2021**, 16, e0259114	3.7	1
172	Presence of anti-TIF-1□anti-Ro52, anti-SSA/Ro60 and anti-Su/Ago2 antibodies in breast cancer: a cross-sectional study. *Immunopharmacology and Immunotoxicology*, **2021**, 43, 328-333	3.2	0
171	Autoantibody Discovery, Assay Development and Adoption: Death Valley, the Sea of Survival and Beyond. *Frontiers in Immunology*, **2021**, 12, 679613	8.4	5
170	Autoantibody profiles delineate distinct subsets of scleromyositis. *Rheumatology*, **2021**,	3.9	2
169	Histopathological features of systemic sclerosis-associated myopathy: A scoping review. *Autoimmunity Reviews*, **2021**, 20, 102851	13.6	3
168	Anti-Ku antibodies: important points to consider. *Annals of the Rheumatic Diseases*, **2021**, 80, e182	2.4	1
167	Anti-Th/To Antibodies: Association With Lung Disease and Potential Protection From Systemic Sclerosis-Related Cancer? Comment on the Article by Mecoli et al. *Arthritis and Rheumatology*, **2021**, 73, 545-546	9.5	1
166	Influenza A (H3N2) infection followed by anti-signal recognition particle antibody-positive necrotizing myopathy: A case report. *International Journal of Infectious Diseases*, **2021**, 103, 33-36	10.5	1

165	Comment on: The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity. *Rheumatology*, **2021**, 60, e35-e37	3.9	3
164	Lung transplantation resulted in marked improvement of autoimmunity and scleroderma in diffuse cutaneous systemic sclerosis: a case report. *Rheumatology*, **2021**, 60, e129-e131	3.9	
163	Immune recognition of lysyl-tRNA synthetase and isoleucyl-tRNA synthetase by anti-OJ antibody-positive sera. *Journal of Autoimmunity*, **2021**, 122, 102680	15.5	3
162	Autoantibodies as biomarkers for interstitial lung disease in idiopathic inflammatory myositis and systemic sclerosis: The case of anti-eIF2B antibodies. *Journal of Translational Autoimmunity*, **2020**, 3, 100049	4.1	4
161	Subacute cutaneous lupus erythematosus with melanocyte elimination induced by pembrolizumab. *Journal of Dermatology*, **2020**, 47, e217-e219	1.6	4
160	Tumour necrosis factor alpha promotes secretion of 14-3-3 by inducing necroptosis in macrophages. *Arthritis Research and Therapy*, **2020**, 22, 24	5.7	8
159	Establishment of international autoantibody reference standards for the detection of autoantibodies directed against PML bodies, GW bodies, and NuMA protein. *Clinical Chemistry and Laboratory Medicine*, **2020**, 59, 197-207	5.9	2
158	Recognising the spectrum of scleromyositis: HEp-2 ANA patterns allow identification of a novel clinical subset with anti-SMN autoantibodies. *RMD Open*, **2020**, 6,	5.9	9
157	Evaluation of a novel particle-based assay for detection of autoantibodies in idiopathic inflammatory myopathies. *Journal of Immunological Methods*, **2019**, 474, 112661	2.5	8
156	Alpha-1-Antitrypsin Ameliorates Pristane Induced Diffuse Alveolar Hemorrhage in Mice. *Journal of Clinical Medicine*, **2019**, 8,	5.1	5
155	Distinctive association of peripheral immune cell phenotypes with capillaroscopic microvascular patterns in systemic sclerosis. *Rheumatology*, **2019**, 58, 2273-2283	3.9	12
154	Autoantibodies to a novel Rpp38 (Th/To) derived B-cell epitope are specific for systemic sclerosis and associate with a distinct clinical phenotype. *Rheumatology*, **2019**, 58, 1784-1793	3.9	2
153	Establishment of an international autoantibody reference standard for human anti-DFS70 antibodies: proof-of-concept study for a novel Megapool strategy by pooling individual specific sera. *Clinical Chemistry and Laboratory Medicine*, **2019**, 57, 1754-1763	5.9	10
152	Anti-OJ autoantibodies: Rare or underdetected?. *Autoimmunity Reviews*, **2019**, 18, 658-664	13.6	25
151	Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective. *Annals of the Rheumatic Diseases*, **2019**, 78, 879-889	2.4	128
150	Standardisation of myositis-specific antibodies: where are we today?. *Annals of the Rheumatic Diseases*, **2019**,	2.4	10
149	Small Cell Lung Cancer Patient with Anti-transcriptional Intermediary Factor 1 Antibody Who Developed Dermatomyositis after Successful Chemoradiotherapy. *Internal Medicine*, **2019**, 58, 427-431	1.1	2
148	Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis. *Internal Medicine*, **2019**, 58, 837-841	1.1	18

147	The two cases of acute acalculous cholecystitis associated with systemic lupus erythematosus (SLE) presented different clinical aspects. *Modern Rheumatology Case Reports*, **2019**, 3, 114-118	0.4	1
146	Reference standards for the detection of anti-mitochondrial and anti-rods/rings autoantibodies. *Clinical Chemistry and Laboratory Medicine*, **2018**, 56, 1789-1798	5.9	13
145	International Consensus on Antinuclear Antibody Patterns: defining negative results and reporting unidentified patterns. *Clinical Chemistry and Laboratory Medicine*, **2018**, 56, 1799-1802	5.9	18
144	Autoantibodies to the survival of motor neuron complex in a patient with necrotizing autoimmune myopathy. *Rheumatology*, **2018**, 57, 199-200	3.9	6
143	Detection of anti-mitochondrial antibodies by immunoprecipitation in patients with systemic sclerosis. *Journal of Immunological Methods*, **2018**, 452, 1-5	2.5	10
142	Elevated □defensin levels in plasma and bronchoalveolar lavage fluid from patients with myositis-associated interstitial lung disease. *BMC Pulmonary Medicine*, **2018**, 18, 44	3.5	3
141	Relevance of interferon-gamma in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis. *Arthritis Research and Therapy*, **2018**, 20, 240	5.7	20
140	International consensus on antinuclear antibody patterns: definition of the AC-29 pattern associated with antibodies to DNA topoisomerase I. *Clinical Chemistry and Laboratory Medicine*, **2018**, 56, 1783-1788	5.9	32
139	A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy. *Clinical Reviews in Allergy and Immunology*, **2017**, 52, 1-19	12.3	184
138	Spontaneous Improvement of Interstitial Pneumonia with Autoimmune Features. *Internal Medicine*, **2017**, 56, 1607-1608	1.1	
137	Clinical characteristics of patients with anti-aminoacyl-tRNA synthetase antibody positive idiopathic interstitial pneumonia. *Respiratory Medicine*, **2017**, 132, 189-194	4.6	17
136	Autoantibodies to Su/Argonaute 2 in Japanese patients with inflammatory myopathy. *Clinica Chimica Acta*, **2017**, 471, 304-307	6.2	6
135	Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis. *Clinical Rheumatology*, **2017**, 36, 469-475	3.9	38
134	B Cell Tolerance to Deiminated Histones in BALB/c, C57BL/6, and Autoimmune-Prone Mouse Strains. *Frontiers in Immunology*, **2017**, 8, 362	8.4	6
133	Calcinosis in poly-dermatomyositis: clinical and laboratory predictors and treatment options. *Clinical and Experimental Rheumatology*, **2017**, 35, 303-308	2.2	15
132	Ethnic Differences in Autoantibody Diversity and Hierarchy: More Clues from a US Cohort of Patients with Systemic Sclerosis. *Journal of Rheumatology*, **2016**, 43, 1816-1824	4.1	15
131	Periodontal bacterial colonization in synovial tissues exacerbates collagen-induced arthritis in B10.RIII mice. *Arthritis Research and Therapy*, **2016**, 18, 161	5.7	30
130	Anti-rods/rings autoantibody seropositivity does not affect response to telaprevir treatment for chronic hepatitis C infection. *Autoimmunity Highlights*, **2016**, 7, 15	3.7	9

129	Report on the second International Consensus on ANA Pattern (ICAP) workshop in Dresden 2015. *Lupus*, **2016**, 25, 797-804	2.6	62
128	International consensus on ANA patterns (ICAP): the bumpy road towards a consensus on reporting ANA results. *Autoimmunity Highlights*, **2016**, 7, 1	3.7	86
127	Clinical subsets associated with different anti-aminoacyl transfer RNA synthetase antibodies and their association with coexisting anti-Ro52. *Modern Rheumatology*, **2016**, 26, 403-9	3.3	26
126	Associations Between Selected Xenobiotics and Antinuclear Antibodies in the National Health and Nutrition Examination Survey, 1999-2004. *Environmental Health Perspectives*, **2016**, 124, 426-36	8.4	17
125	Interleukin 1Responsive MicroRNA-146a Is Critical for the Cytokine-Induced Tolerance and Cross-Tolerance to Toll-Like Receptor Ligands. *Journal of Innate Immunity*, **2015**, 7, 428-40	6.9	43
124	The uses and misuses of multiplex autoantibody assays in systemic autoimmune rheumatic diseases. *Frontiers in Immunology*, **2015**, 6, 181	8.4	30
123	Influenza Vaccine and Autoimmune Diseases **2015**, 175-184		2
122	Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014-2015. *Frontiers in Immunology*, **2015**, 6, 412	8.4	193
121	AB0794 Protein and Rna-Immunoprecipitation for the Identification of Autoantibodies in Patients Affected by Psoriatic Arthritis. *Annals of the Rheumatic Diseases*, **2015**, 74, 1164.4-1165	2.4	
120	Autoantibodies to the mitochondrial RNA processing (MRP) complex also known as Th/To autoantigen. *Autoimmunity Reviews*, **2015**, 14, 254-7	13.6	22
119	Positive correlation of STAT1 and miR-146a with anemia in patients with systemic lupus erythematosus. *Journal of Clinical Immunology*, **2014**, 34, 171-80	5.7	18
118	Reduced levels of CCL2 and CXCL10 in systemic lupus erythematosus patients under treatment with prednisone, mycophenolate mofetil, or hydroxychloroquine, except in a high STAT1 subset. *Arthritis Research and Therapy*, **2014**, 16, R23	5.7	18
117	Elevated signal transducers and activators of transcription 1 correlates with increased C-C motif chemokine ligand 2 and C-X-C motif chemokine 10 levels in peripheral blood of patients with systemic lupus erythematosus. *Arthritis Research and Therapy*, **2014**, 16, R20	5.7	15
116	Autoantibodies to the Rpp25 component of the Th/To complex are the most common antibodies in patients with systemic sclerosis without antibodies detectable by widely available commercial tests. *Journal of Rheumatology*, **2014**, 41, 1334-43	4.1	16
115	AB0635 Clinical and Autoantibodies Features in Autoimmune/Inflammatory Syndrome Induced by Adjuvants: Mineral Oils and Silicone. *Annals of the Rheumatic Diseases*, **2014**, 73, 1015.3-1016	2.4	
114	Molecular cell biology and immunobiology of mammalian rod/ring structures. *International Review of Cell and Molecular Biology*, **2014**, 308, 35-74	6	40
113	Differential reactivity to IMPDH2 by anti-rods/rings autoantibodies and unresponsiveness to pegylated interferon-alpha/ribavirin therapy in US and Italian HCV patients. *Journal of Clinical Immunology*, **2013**, 33, 420-6	5.7	37
112	Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara. *Arthritis Research and Therapy*, **2013**, 15, R48	5.7	50

111	Rpp25 is a major target of autoantibodies to the Th/To complex as measured by a novel chemiluminescent assay. *Arthritis Research and Therapy*, **2013**, 15, R50	5.7	17
110	MicroRNA-146a in autoimmunity and innate immune responses. *Annals of the Rheumatic Diseases*, **2013**, 72 Suppl 2, ii90-5	2.4	61
109	Autoantibodies to Argonaute 2 (Su antigen). *Advances in Experimental Medicine and Biology*, **2013**, 768, 45-59	3.6	18
108	Regulation of TLR2-mediated tolerance and cross-tolerance through IRAK4 modulation by miR-132 and miR-212. *Journal of Immunology*, **2013**, 190, 1250-63	5.3	125
107	AB0239 Autoantibody profile in a cohort of adult patients with inflammatory myophaties. *Annals of the Rheumatic Diseases*, **2013**, 71, 651.4-651	2.4	
106	FRI0389 First report of anti-mda5 antibodies in a cohort of italian patients with dermatomyositis: clinical and serologic correlations. *Annals of the Rheumatic Diseases*, **2013**, 72, A504.3-A505	2.4	
105	Common pathways of autoimmune inflammatory myopathies and genetic neuromuscular disorders. *Clinical Reviews in Allergy and Immunology*, **2012**, 42, 16-25	12.3	6
104	MicroRNAs and autoimmunity. *Current Opinion in Immunology*, **2012**, 24, 686-91	7.8	66
103	Autoantibodies to transcription intermediary factor TIF1□associated with dermatomyositis. *Arthritis Research and Therapy*, **2012**, 14, R79	5.7	20
102	Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. *Arthritis and Rheumatism*, **2012**, 64, 2319-27		241
101	A new immunoprecipitation-real time quantitative PCR assay for anti-Th/To and anti-U3RNP antibody detection in systemic sclerosis. *Arthritis Research and Therapy*, **2012**, 14, R128	5.7	7
100	Coexistence of anti-RNA polymerase III and anti-U1RNP antibodies in patients with systemic lupus erythematosus: two cases without features of scleroderma. *Lupus*, **2012**, 21, 68-74	2.6	2
99	Pleiotropic IFN-dependent and -independent effects of IRF5 on the pathogenesis of experimental lupus. *Journal of Immunology*, **2012**, 188, 4113-21	5.3	48
98	Atypical clinical presentation of a subset of patients with anti-RNA polymerase III--non-scleroderma cases associated with dominant RNA polymerase I reactivity and nucleolar staining. *Arthritis Research and Therapy*, **2011**, 13, R119	5.7	4
97	Frequent coexistence of anti-topoisomerase I and anti-U1RNP autoantibodies in African American patients associated with mild skin involvement: a retrospective clinical study. *Arthritis Research and Therapy*, **2011**, 13, R73	5.7	4
96	Polyclonal hypergammaglobulinemia and autoantibody production induced by vaccination in farmed Atlantic salmon. *Fish and Shellfish Immunology*, **2011**, 30, 1080-6	4.3	12
95	MicroRNA in TLR signaling and endotoxin tolerance. *Cellular and Molecular Immunology*, **2011**, 8, 388-403	15.4	225
94	Antihistone and Antispliceosomal Antibodies **2011**, 275-292		2

93	Induction of cytoplasmic rods and rings structures by inhibition of the CTP and GTP synthetic pathway in mammalian cells. *PLoS ONE*, **2011**, 6, e29690	3.7	129
92	MicroRNAs in rheumatoid arthritis. *FEBS Letters*, **2011**, 585, 3667-74	3.8	76
91	Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies. *Clinical Rheumatology*, **2011**, 30, 1333-9	3.9	36
90	Autoantibodies to survival of motor neuron complex in patients with polymyositis: immunoprecipitation of D, E, F, and G proteins without other components of small nuclear ribonucleoproteins. *Arthritis and Rheumatism*, **2011**, 63, 1972-8		28
89	MicroRNAs in systemic rheumatic diseases. *Arthritis Research and Therapy*, **2011**, 13, 229	5.7	87
88	Anti-argonaute2 (Ago2/Su) and -Ro antibodies identified by immunoprecipitation in primary anti-phospholipid syndrome (PAPS). *Autoimmunity*, **2011**, 44, 90-7	3	12
87	Mechanistic role of microRNA-146a in endotoxin-induced differential cross-regulation of TLR signaling. *Journal of Immunology*, **2011**, 186, 1723-34	5.3	172
86	IL-1□modulates neutrophil recruitment in chronic inflammation induced by hydrocarbon oil. *Journal of Immunology*, **2011**, 186, 1747-54	5.3	45
85	Anti-MIT3 antibodies in systemic sclerosis. *Annals of the Rheumatic Diseases*, **2011**, 70, A84-A84	2.4	
84	Autoantibodies and Autoantigens in Sj□gren□ Syndrome **2011**, 111-132		
83	Formation of GW/P bodies as marker for microRNA-mediated regulation of innate immune signaling in THP-1 cells. *Immunology and Cell Biology*, **2010**, 88, 205-12	5	30
82	Anti-Th/To are common antinucleolar autoantibodies in Italian patients with scleroderma. *Journal of Rheumatology*, **2010**, 37, 2071-5	4.1	40
81	Manifestations of systemic autoimmunity in vaccinated salmon. *Vaccine*, **2010**, 28, 4961-9	4.1	47
80	High prevalence of autoantibodies to RNA helicase A in Mexican patients with systemic lupus erythematosus. *Arthritis Research and Therapy*, **2010**, 12, R6	5.7	8
79	Autoantibodies to a miRNA-binding protein Argonaute2 (Su antigen) in patients with hepatitis C virus infection. *Clinical and Experimental Rheumatology*, **2010**, 28, 842-8	2.2	6
78	miR-146a is critical for endotoxin-induced tolerance: IMPLICATION IN INNATE IMMUNITY. *Journal of Biological Chemistry*, **2009**, 284, 34590-9	5.4	306
77	B cell proliferation, somatic hypermutation, class switch recombination, and autoantibody production in ectopic lymphoid tissue in murine lupus. *Journal of Immunology*, **2009**, 182, 4226-36	5.3	44
76	Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. *Trends in Immunology*, **2009**, 30, 455-64	14.4	248

75	Reduced IgG anti-small nuclear ribonucleoprotein autoantibody production in systemic lupus erythematosus patients with positive IgM anti-cytomegalovirus antibodies. *Arthritis Research and Therapy*, **2009**, 11, R27	5.7	19
74	Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases. *Modern Rheumatology*, **2009**, 19, 219-228	3.3	88
73	Autoantibody to NA14 is an independent marker primarily for Sjogren's syndrome. *Frontiers in Bioscience - Landmark*, **2009**, 14, 3733-9	2.8	17
72	Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases. *Modern Rheumatology*, **2009**, 19, 219-28	3.3	44
71	Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. *Arthritis Research and Therapy*, **2008**, 10, R101	5.7	513
70	Identification of GW182 and its novel isoform TNGW1 as translational repressors in Ago2-mediated silencing. *Journal of Cell Science*, **2008**, 121, 4134-44	5.3	55
69	A novel type I IFN-producing cell subset in murine lupus. *Journal of Immunology*, **2008**, 180, 5101-8	5.3	96
68	Colocalization of antigen-specific B and T cells within ectopic lymphoid tissue following immunization with exogenous antigen. *Journal of Immunology*, **2008**, 181, 3259-67	5.3	14
67	TLR7-dependent and FcgammaR-independent production of type I interferon in experimental mouse lupus. *Journal of Experimental Medicine*, **2008**, 205, 2995-3006	16.6	171
66	Vaccination-induced systemic autoimmunity in farmed Atlantic salmon. *Journal of Immunology*, **2008**, 181, 4807-14	5.3	94
65	Patients with pulmonary tuberculosis are frequently positive for anti-cyclic citrullinated peptide antibodies, but their sera also react with unmodified arginine-containing peptide. *Arthritis and Rheumatism*, **2008**, 58, 1576-81		59
64	The role of GW/P-bodies in RNA processing and silencing. *Journal of Cell Science*, **2007**, 120, 1317-23	5.3	107
63	Autoantibodies to RNA helicase A: a new serologic marker of early lupus. *Arthritis and Rheumatism*, **2007**, 56, 596-604		44
62	Deficiency of the type I interferon receptor protects mice from experimental lupus. *Arthritis and Rheumatism*, **2007**, 56, 3770-83		152
61	Clinical implication of autoantibodies in patients with systemic rheumatic diseases. *Expert Review of Clinical Immunology*, **2007**, 3, 721-38	5.1	54
60	Small interfering RNA-mediated silencing induces target-dependent assembly of GW/P bodies. *Molecular Biology of the Cell*, **2007**, 18, 3375-87	3.5	42
59	Role of non-protein amino acid L-canavanine in autoimmunity. *Autoimmunity Reviews*, **2006**, 5, 429-35	13.6	34
58	Detection of the argonaute protein Ago2 and microRNAs in the RNA induced silencing complex (RISC) using a monoclonal antibody. *Journal of Immunological Methods*, **2006**, 317, 38-44	2.5	66

57	Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis/dermatomyositis. *Arthritis and Rheumatism*, **2006**, 54, 2004-9		81
56	Nucleolar staining cannot be used as a screening test for the scleroderma marker anti-RNA polymerase I/III antibodies. *Arthritis and Rheumatism*, **2006**, 54, 3051-6		32
55	Role of PGE2 and EP receptors in the pathogenesis of rheumatoid arthritis and as a novel therapeutic strategy. *Endocrine, Metabolic and Immune Disorders - Drug Targets*, **2006**, 6, 383-94	2.2	75
54	Autoantibodies against the replication protein A complex in systemic lupus erythematosus and other autoimmune diseases. *Arthritis Research and Therapy*, **2006**, 8, R111	5.7	19
53	Autoimmune targeting of key components of RNA interference. *Arthritis Research and Therapy*, **2006**, 8, R87	5.7	86
52	Type I interferon production by tertiary lymphoid tissue developing in response to 2,6,10,14-tetramethyl-pentadecane (pristane). *American Journal of Pathology*, **2006**, 168, 1227-40	5.8	90
51	Induction of lupus-related specific autoantibodies by non-specific inflammation caused by an intraperitoneal injection of n-hexadecane in BALB/c mice. *Toxicology*, **2006**, 218, 186-96	4.4	16
50	Pristane-induced autoimmunity in germ-free mice. *Clinical Immunology*, **2005**, 114, 110-8	9	32
49	Association of anti-nucleoprotein autoantibodies with upregulation of Type I interferon-inducible gene transcripts and dendritic cell maturation in systemic lupus erythematosus. *Clinical Immunology* , **2005**, 117, 238-50	9	63
48	Disruption of GW bodies impairs mammalian RNA interference. *Nature Cell Biology*, **2005**, 7, 1267-74	23.4	368
47	Distinctive patterns of autoimmune response induced by different types of mineral oil. *Toxicological Sciences*, **2004**, 78, 222-8	4.4	44
46	ORIGINS OF ANTINUCLEAR ANTIBODIES **2004**, 401-431		1
45	Induction of Autoimmunity by Adjuvant Hydrocarbons **2004**, 87-104		1
44	Autoantibodies that stabilize U1snRNP are a significant component of human autoantibodies to snRNP and delay proteolysis of sm antigens in vitro. *Journal of Rheumatology*, **2004**, 31, 2382-9	4.1	4
43	Ecotropic murine leukemia viruses and exogenous mouse mammary tumor viruses are not essential for pristane-induced lupus. *Arthritis and Rheumatism*, **2003**, 48, 2990-2		3
42	Nephritogenic autoantibodies but absence of nephritis in Il-12p35-deficient mice with pristane-induced lupus. *Kidney International*, **2003**, 64, 897-905	9.9	41
41	Induction of lupus autoantibodies by adjuvants. *Journal of Autoimmunity*, **2003**, 21, 1-9	15.5	82
40	Immunoregulatory role of CD1d in the hydrocarbon oil-induced model of lupus nephritis. *Journal of Immunology*, **2003**, 171, 2142-53	5.3	86

39	X-linked immunodeficient mice spontaneously produce lupus-related anti-RNA helicase A autoantibodies, but are resistant to pristane-induced lupus. *International Immunology*, **2003**, 15, 1117-24	4.9	17
38	Effect of an exogenous trigger on the pathogenesis of lupus in (NZB x NZW)F1 mice. *Arthritis and Rheumatism*, **2002**, 46, 2235-44		39
37	Interferon-gamma is required for lupus nephritis in mice treated with the hydrocarbon oil pristane. *Kidney International*, **2001**, 60, 2173-80	9.9	91
36	Increased prevalence of autoantibodies to ku antigen in African American versus white patients with systemic lupus erythematosus. *Arthritis and Rheumatism*, **2001**, 44, 2367-70		39
35	Titration emulation: a computer-assisted technique that simplifies the quantification of anti-dsDNA antibodies using the Crithidia luciliae assay. *Lupus*, **2001**, 10, 632-6	2.6	1
34	Widespread susceptibility among inbred mouse strains to the induction of lupus autoantibodies by pristane. *Clinical and Experimental Immunology*, **2000**, 121, 399-405	6.2	92
33	Fas and Fas ligand mutations inhibit autoantibody production in pristane-induced lupus. *Journal of Immunology*, **2000**, 165, 1036-43	5.3	58
32	Induction of hypergammaglobulinemia and macrophage activation by silicone gels and oils in female A.SW mice. *Vaccine Journal*, **2000**, 7, 366-70		26
31	B cell subsets in pristane-induced autoimmunity. *Current Topics in Microbiology and Immunology*, **2000**, 252, 201-7	3.3	4
30	Immunopathogenesis of environmentally induced lupus in mice. *Environmental Health Perspectives*, **1999**, 107 Suppl 5, 723-7	8.4	31
29	Disparate T cell requirements of two subsets of lupus-specific autoantibodies in pristane-treated mice. *Clinical and Experimental Immunology*, **1999**, 115, 547-53	6.2	26
28	Autoantibodies define a family of proteins with conserved double-stranded RNA-binding domains as well as DNA binding activity. *Journal of Biological Chemistry*, **1999**, 274, 34598-604	5.4	35
27	Influence of microbial stimulation on hypergammaglobulinemia and autoantibody production in pristane-induced lupus. *Clinical Immunology and Immunopathology*, **1998**, 86, 271-9		43
26	Interleukin 6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus. *Journal of Experimental Medicine*, **1998**, 188, 985-90	16.6	167
25	Human anti-nuclear ribonucleoprotein antigen autoimmune sera contain a novel subset of autoantibodies that stabilizes the molecular interaction of U1RNP-C protein with the Sm core proteins. *Journal of Immunology*, **1997**, 158, 5017-25	5.3	25
24	Recombinant 52 kDa Ro(SSA) ELISA detects autoantibodies in Sjögren's syndrome sera that go undetected by conventional serologic assays. *Journal of Rheumatology*, **1997**, 24, 860-6	4.1	25
23	Autoantibodies that stabilize the molecular interaction of Ku antigen with DNA-dependent protein kinase catalytic subunit. *Clinical and Experimental Immunology*, **1996**, 105, 460-7	6.2	26
22	Distinctive immune response patterns of human and murine autoimmune sera to U1 small nuclear ribonucleoprotein C protein. *Journal of Clinical Investigation*, **1996**, 97, 2619-26	15.9	38

21	Ku and Ki Autoantibodies **1996**, 449-455		1
20	Clinical significance of autoantibodies to Ku and related antigens **1996**, 617-627		
19	Ku and related antigens **1996**, 343-364		
18	Autoantibodies to ribosomal P antigens with immune complex glomerulonephritis in SJL mice treated with pristane. *Journal of Immunology*, **1996**, 157, 3200-6	5.3	48
17	Absence of autoantigen Ku in mature human neutrophils and human promyelocytic leukemia line (HL-60) cells and lymphocytes undergoing apoptosis. *Journal of Experimental Medicine*, **1995**, 181, 2049-58	16.6	53
16	Changing autoantibody profiles with variable clinical manifestations in a patient with relapsing systemic lupus erythematosus and polymyositis. *Rheumatology*, **1995**, 34, 915-9	3.9	6
15	Pristane induces high titers of anti-Su and anti-nRNP/Sm autoantibodies in BALB/c mice. Quantitation by antigen capture ELISAs based on monospecific human autoimmune sera. *Journal of Immunological Methods*, **1995**, 182, 51-62	2.5	33
14	Anti-nuclear antibody production and immune-complex glomerulonephritis in BALB/c mice treated with pristane. *Proceedings of the National Academy of Sciences of the United States of America*, **1995**, 92, 10934-8	11.5	158
13	Role of free p70 (Ku) subunit in posttranslational stabilization of newly synthesized p80 during DNA-dependent protein kinase assembly. *European Journal of Cell Biology*, **1995**, 66, 127-35	6.1	27
12	Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristane. *Journal of Experimental Medicine*, **1994**, 180, 2341-6	16.6	235
11	Initiation of autoimmunity to the p53 tumor suppressor protein by complexes of p53 and SV40 large T antigen. *Journal of Experimental Medicine*, **1994**, 179, 1243-52	16.6	105
10	Characterization of the Su antigen, a macromolecular complex of 100/102 and 200-kDa proteins recognized by autoantibodies in systemic rheumatic diseases. *Clinical Immunology and Immunopathology*, **1994**, 73, 132-41		37
9	Similar DNA binding properties of free P70 (KU) subunit and P70/P80 heterodimer. *FEBS Letters*, **1994**, 351, 219-24	3.8	26
8	Onset of polymyositis with autoantibodies to threonyl-tRNA synthetase during pregnancy. *Journal of Rheumatology*, **1994**, 21, 1564-6	4.1	24
7	Association of autoantibodies to topoisomerase I and the phosphorylated (IIO) form of RNA polymerase II in Japanese scleroderma patients. *Journal of Immunology*, **1994**, 153, 5838-48	5.3	28
6	Autoantibodies to RNA polymerase II are common in systemic lupus erythematosus and overlap syndrome. Specific recognition of the phosphorylated (IIO) form by a subset of human sera. *Journal of Clinical Investigation*, **1994**, 94, 1981-9	15.9	56
5	Assembly and DNA binding of recombinant Ku (p70/p80) autoantigen defined by a novel monoclonal antibody specific for p70/p80 heterodimers. *Journal of Cell Science*, **1994**, 107, 3223-3233	5.3	37
4	Clinical applications of an anti-ku antigen-capture ELISA. *Clinical Immunology Newsletter*, **1993**, 13, 23-31		7

3	A case of long-standing classical rheumatoid arthritis complicated by serological and clinical characteristics of SLE. *Scandinavian Journal of Rheumatology*, **1993**, 22, 138-40	1.9	8
2	Murine monoclonal antibodies specific for conserved and non-conserved antigenic determinants of the human and murine Ku autoantigens. *Molecular Biology Reports*, **1993**, 18, 15-28	2.8	47
1	B-cell epitopes of autoantigenic DNA-binding proteins. *Molecular Biology Reports*, **1992**, 16, 191-8	2.8	12